Notable Labs shares are trading lower. The company announced progress for its Phase 2 volasertib program.
Portfolio Pulse from Benzinga Newsdesk
Notable Labs shares are trading lower following the company's announcement of progress in its Phase 2 volasertib program.
July 24, 2024 | 11:52 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Notable Labs shares are experiencing a decline after the company announced progress in its Phase 2 volasertib program.
The announcement of progress in the Phase 2 volasertib program has led to a negative market reaction, causing a decline in Notable Labs' share price. This could be due to investor concerns about the costs and risks associated with clinical trials.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100